STCube announced on the 16th that it had received approval from the Ministry of Food and Drug Safety for a phase 1 clinical trial plan for hSTC810, an immunotherapy for solid cancer patients.
This clinical trial will be conducted simultaneously in the US and Korea. ST Cube also received approval from the US Food and Drug Administration in January for a clinical trial plan for this candidate. In Korea, it plans to conduct clinical trials in two places: Sinchon Severance Hospital and Korea University Anam Hospital. hSTC810 is effective by blocking the activity of PD-L1, a protein that interferes with the activity of immune cells on the surface of cancer cells. It targets BTN1A1, a substance that regulates the activity of this protein. BTN1A1 is a target substance discovered by ST Cube for the first time in the world.
“Several pharmaceutical companies that are discussing technology transfer are conducting due diligence,” said Hyunjin Jeong, CEO of ST Cube. He also said, “As we have received approval from the clinical trial review committee at the two hospitals where we will conduct clinical trials, we will start registering the first patients soon.”
